Logo image of GLSI

GREENWICH LIFESCIENCES INC (GLSI) Stock Fundamental Analysis

NASDAQ:GLSI - Nasdaq - US3968791083 - Common Stock - Currency: USD

8.99  +0.06 (+0.67%)

After market: 9.09 +0.1 (+1.11%)

Fundamental Rating

1

GLSI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. GLSI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLSI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GLSI had negative earnings in the past year.
In the past year GLSI has reported a negative cash flow from operations.
In the past 5 years GLSI always reported negative net income.
GLSI had a negative operating cash flow in each of the past 5 years.
GLSI Yearly Net Income VS EBIT VS OCF VS FCFGLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

GLSI has a Return On Assets of -602.52%. This is amonst the worse of the industry: GLSI underperforms 97.13% of its industry peers.
With a Return On Equity value of -1262.97%, GLSI is not doing good in the industry: 82.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -602.52%
ROE -1262.97%
ROIC N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
GLSI Yearly ROA, ROE, ROICGLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

GLSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLSI Yearly Profit, Operating, Gross MarginsGLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

GLSI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GLSI has more shares outstanding
There is no outstanding debt for GLSI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLSI Yearly Shares OutstandingGLSI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GLSI Yearly Total Debt VS Total AssetsGLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -4.72, we must say that GLSI is in the distress zone and has some risk of bankruptcy.
GLSI's Altman-Z score of -4.72 is in line compared to the rest of the industry. GLSI outperforms 40.86% of its industry peers.
GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.72
ROIC/WACCN/A
WACCN/A
GLSI Yearly LT Debt VS Equity VS FCFGLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.91 indicates that GLSI should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.91, GLSI is doing worse than 77.24% of the companies in the same industry.
GLSI has a Quick Ratio of 1.91. This is a normal value and indicates that GLSI is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.91, GLSI is not doing good in the industry: 75.99% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 1.91
GLSI Yearly Current Assets VS Current LiabilitesGLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

GLSI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.08%.
EPS 1Y (TTM)-74.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLSI Yearly EPS VS EstimatesGLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLSI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLSI Price Earnings VS Forward Price EarningsGLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLSI Per share dataGLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GLSI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GREENWICH LIFESCIENCES INC

NASDAQ:GLSI (6/27/2025, 8:17:06 PM)

After market: 9.09 +0.1 (+1.11%)

8.99

+0.06 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-20 2025-05-20/amc
Earnings (Next)08-12 2025-08-12
Inst Owners9.47%
Inst Owner Change-1.03%
Ins Owners54.28%
Ins Owner Change0.41%
Market Cap120.20M
Analysts82.86
Price Target39.78 (342.49%)
Short Float %15.71%
Short Ratio12.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-93.45%
Min EPS beat(2)-184.78%
Max EPS beat(2)-2.12%
EPS beat(4)2
Avg EPS beat(4)-44.58%
Min EPS beat(4)-184.78%
Max EPS beat(4)6.63%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 91.59
P/tB 91.65
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -602.52%
ROE -1262.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 1.91
Altman-Z -4.72
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y20.1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-74.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.96%
OCF growth 3YN/A
OCF growth 5YN/A